In a nutshell
This study will thoroughly test a new drug, which should work
when current hormone therapies fail, in the lab, so that it can go
on to be tested in the clinic.
Why we funded it
Prostate cancer growth is dependent on hormones called androgens
(eg testosterone), which promote cell growth. Androgens bind to and
activate the androgen receptor (AR) and many current therapies
target either androgen production or AR activity.
However, cancers may become resistant to this hormone
therapy. When this happens, relapse is common and results in
the return of aggressive prostate cancer. Therefore, better methods
of targeting the AR are required to prevent the cycle of resistance
and relapse. This project proposes a new way to inhibit the AR that
works even in the presence of hormones.
Read a more detailed summary of this project here.